Fidelity Investments
SABS icon

Fidelity Investments’s SAB Biotherapeutics SABS Stock Holding History

Fidelity Investments’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-34
Closed -$236 – 5664
2023
Q4 		$236 Hold
34
– – ﹤0.01% 4870
2023
Q3 		$216 Buy
+34
New +$250 ﹤0.01% 4782
2022
Q4 		– Sell
-900
Closed -$6K – 5558
2022
Q3 		$6K Buy
+900
New +$8.93K ﹤0.01% 4265

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fidelity Investments's SABS Position: Q1 2024 in Review

Fidelity Investments sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 34 shares — an estimated $236 sold.

Fidelity Investments first reported a position in SABS in Q3 2022 and held it in 3 quarters. The position peaked at $6K in Q3 2022. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Fidelity Investments reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Fidelity Investments sold 34 SAB Biotherapeutics shares in Q1 2024, an estimated $236.
  • Fidelity Investments first reported a position in SAB Biotherapeutics in Q3 2022 and held it in 3 quarters.
  • Fidelity Investments's SAB Biotherapeutics position peaked at $6K in Q3 2022.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.